



## Strengthening the Nation's Capacity to Respond to Domestic Infectious Diseases

CDC's *Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases Cooperative Agreement* (ELC) provides financial support and technical assistance to the nation's health departments to **detect, prevent, and respond to emerging infectious diseases**. ELC's **64 recipients**, which consist of state, large local, and U.S. territory and affiliate health departments, serve as the foundation for our national public health infrastructure and are integral to the nation's ability to tackle infectious disease threats.

The ELC accomplishes its mission by awarding critical support for core public health programs and a range of disease-specific projects. ELC also distributes supplemental funding on behalf of CDC for emergency response efforts, such as those for the influenza H1N1, Zika, and Ebola epidemics, and most recently, the COVID-19 pandemic.

### Our Structure: What Sets ELC Apart




Flexible funding provides recipients **the ability to meet their own changing needs**, instead of a one-size-fits-all strategy.



Disease-specific projects allow for **prioritization of health topics** specific to certain areas or populations, such as rabies surveillance or vaccine-preventable diseases.



Funding for leadership and management supports **strategic planning and management** of ELC resources.



Cross-cutting projects and programs **enhance collaboration** between state epidemiology and laboratory, as well as local public health departments.

**In 2023**, ELC awarded approximately **\$192M to its 64 recipients** in core funding to continue the crucial work of health departments across the United States. This is the final year of the cooperative agreement (CK19-1904) and a new 5-year cooperative agreement will begin in

July 2024. **Learn more about ELC at:** [www.cdc.gov/elc](http://www.cdc.gov/elc)

## 2023-2024: Budget Period 5 Core Funding

Programs	Recipients	Award Amount
Cross-Cutting: Epidemiology & Laboratory Capacity	60	\$19,935,318
Foodborne, Waterborne, Enteric, & Environmentally Transmitted Diseases Program	59	\$34,794,587
Healthcare-associated Infections & Antibiotic Resistance Program	57	\$30,840,497
Vector-Borne Diseases Program	60	\$22,482,966
Cross-Cutting Projects	Recipients	Award Amount
ELC Leadership, Management & Administration	52	\$5,024,903
Health Information Systems Capacity	60	\$37,987,138
Data Modernization	0	\$0*
Impact & Evaluation	2	\$203,609
Cross-Cutting Emerging Issues Project: Enhanced Surveillance, Outbreak Investigation Response & Reporting, Surge Efforts & Interventions	64	<i>Available for emerging issues</i>

Disease- Specific Projects	Recipients	Award Amount
Mycotics: Detecting & Preventing Fungal Infections	31	\$1,011,931
Binational Border Infectious Disease Surveillance (BIDS) Program	4	\$1,304,203
Global Migration, Border Interventions, and Migrant Health	2	\$150,000
Prion Surveillance	6	\$419,347
Rabies Surveillance & Laboratory Capacity	38	\$340,000
Parasitic Disease Surveillance	13	\$80,000
Enhanced Vaccine-Preventable Disease (VPD)	60	\$12,297,604
Legionnaires' Disease Prevention	33	\$1,900,000
Influenza Surveillance and Diagnostic Testing	57	\$9,755,616
Non-Influenza Respiratory Diseases: Diagnostics, Reporting, and Surveillance	46	\$2,000,000
Strengthening US Response to Resistant Gonorrhea (SURRG)	8	\$5,341,999
Gonococcal Isolate Surveillance Project (GISP)	21	\$600,000
Catalyzing Congenital Syphilis Prevention (CCSP)	4	\$1,356,736
Human Papillomavirus Surveillance Among Men	3	\$375,880
Infants with Congenital Exposures: Surveillance and Monitoring to Emerging Infectious Diseases and Other Health Threats	13	\$3,497,208

\*Data Modernization award made through COVID supplemental awards, not as part of the Core ELC funding

<b>Total</b>		<b>\$191,699,542</b>
--------------	--	----------------------